Rongze Lu, PhD
Associate Professor
Neurological Surgery
School of Medicine
I am an Associate Professor in the Department of Neurological Surgery at University of California, San Francisco (UCSF). Our lab focuses on identifying molecular mechanisms mediating immune suppression and evasion in brain tumors, with the goal of developing novel immunotherapeutics for these diseases.
Show full bio (60 words) Hide full bio
My recent research identified that protein phosphatase 2A negatively regulated T cell and macrophage mediated anti-tumor immunity, and further demonstrated that pharmacological inhibition of PP2A synergized with PD-1 blockade in multiple type of resistant tumors including glioblastoma. Based on those findings, a Phase I/II trial (NCT03027388) of PP2A inhibitor in recurrent glioblastoma is ongoing.
Awards
Show all (3) Hide
- DOD Peer Reviewed Cancer Research Program Career Development Award, Department of Defense, 2020
- Keystone Early Career Investigator Award, Keystone Conference, 2020
- H.N. and Frances C. Berger Foundation Fellowship, City of Hope, 2008
Education & Training
Show all (1) Hide
- Ph.D. Cancer Immunology City of Hope 06/2011
Interests
Show all (3) Hide
- Cancer Immunotherapy
- Brain Cancer
- Macrophage/Microglia
Websites
Show all (1) Hide
- Lab Website (lulab.ucsf.edu)
Grants and Projects
Show all (5) Hide
- Regulation of Macrophage- and Microglia-mediated STING Signaling in Glioblastoma, NIH/NINDS, 2022-2027
- Targeting Protein Phosphatase 2A (PP2A) to Overcome Macrophage-Mediated Immunosuppression in Glioblastoma, DOD PRCRP, 2020-2024
- Role of Aberrant Translational Quality Control in Tumorigenesis in Glioblastoma, Cancer Prevention and Research Institute of Texas, 2021-2023
- Novel Strategy to Target PP2A, NIH SPORE Developmental Research Program Award, 2022-2023
- Focused Ultrasound Induced Optogenetic Activation of CAR-Macrophage for Glioblastoma, MDAnderson-UT Austin Collaborative Pilot Project Grant, 2021-2022
Publications (18)
Top publication keywords:
GlioblastomaToll-Like Receptor 4LipopolysaccharidesOxidative PhosphorylationProtein Tyrosine Phosphatase, Non-Receptor Type 6Cell Adhesion MoleculesCarcinoembryonic AntigenMultiprotein ComplexesInterleukin-1betaMyeloid CellsNeutrophil ActivationMelanoma, ExperimentalProtein-Tyrosine KinasesLiposomesPhospholipids
-
PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING-Type I Interferon Signaling in Glioblastoma
Cancer Research 2023 Mondal I, Das O, Sun R, Gao J, Yu B, Diaz A, Behnan J, Dubey A, Meng Z, Eskandar E, Xu B, Lu R*, and Ho W* corresponding author -
PP2A/STRN4 Negatively Regulates STING-Type I Interferon Signaling in Tumor Associated Macrophages
Journal of Clinical Investigation 2023 Ho WS*, Mondal I*, Xu B*, Das O*, Sun R, Chiou P, Lyu J, Li L, Cai X, Tahmasebinia F, Wu C Y-J, Wu Z, Matsui W, Lim M, Meng Z, Lu RO* corresponding author -
Pantothenate kinase 2 interacts with PINK1 to regulate mitochondrial quality control via acetyl-CoA metabolism.
Nature communications 2022 Huang Y, Wan Z, Tang Y, Xu J, Laboret B, Nallamothu S, Yang C, Liu B, Lu RO, Lu B, Feng J, Cao J, Hayflick S, Wu Z, Zhou B -
Targeting Mitochondrial Oxidative Phosphorylation in Glioblastoma Therapy.
Neuromolecular medicine 2021 Wu Z, Ho WS, Lu R -
Mitochondrial Dysfunction, Macrophage, and Microglia in Brain Cancer.
Frontiers in cell and developmental biology 2021 Lu RO, Ho WS
Show all (13 more) Hide
-
Inhibition of protein phosphatase-2A with LB-100 enhances antitumor immunity against glioblastoma
J Neurooncol. 2020 Maggio D, Ho WS, Breese R, Walbridge S, Wang H, Cui J, Heiss JD, Gilbert MR, Kovach JS, Lu RO*, Zhuang Z. corresponding author -
Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade
Nat Commun. 2019 Ho WS, Wang H, Maggio D, Kovach JS, Zhang Q, Song Q, Marincola FM, Heiss JD, Gilbert MR, Lu R* corresponding author -
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
Journal for immunotherapy of cancer 2019 Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT… -
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA).
Journal for immunotherapy of cancer 2018 Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, Wallden B, Marincola FM, Cesano A -
Immune oncology, immune responsiveness and the theory of everything.
Journal for immunotherapy of cancer 2018 Turan T, Kannan D, Patel M, Matthew Barnes J, Tanlimco SG, Lu R, Halliwill K, Kongpachith S, Kline DE, Hendrickx W, Cesano A, Butterfield LH, Kaufman HL, Hudson TJ, Bedognetti D, Marincola F, Samayoa … -
Cancer immune resistance: can theories converge?
Emerging topics in life sciences 2017 Lu R, Turan T, Samayoa J, Marincola FM -
LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation.
Cancer letters 2017 Ho WS, Sizdahkhani S, Hao S, Song H, Seldomridge A, Tandle A, Maric D, Kramp T, Lu R, Heiss JD, Camphausen K, Gilbert MR, Zhuang Z, Park DM -
Deubiquitinase DUBA is a post-translational brake on interleukin-17 production in T cells.
Nature 2014 Rutz S, Kayagaki N, Phung QT, Eidenschenk C, Noubade R, Wang X, Lesch J, Lu R, Newton K, Huang OW, Cochran AG, Vasser M, Fauber BP, DeVoss J, Webster J, Diehl L, Modrusan Z, Kirkpatrick DS, Lill JR, … -
NRROS negatively regulates reactive oxygen species during host defence and autoimmunity.
Nature 2014 Noubade R, Wong K, Ota N, Rutz S, Eidenschenk C, Valdez PA, Ding J, Peng I, Sebrell A, Caplazi P, DeVoss J, Soriano RH, Sai T, Lu R, Modrusan Z, Hackney J, Ouyang W -
G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells.
The Journal of biological chemistry 2013 Xin H, Lu R, Lee H, Zhang W, Zhang C, Deng J, Liu Y, Shen S, Wagner KU, Forman S, Jove R, Yu H -
CEACAM1 negatively regulates IL-1β production in LPS activated neutrophils by recruiting SHP-1 to a SYK-TLR4-CEACAM1 complex.
PLoS pathogens 2012 Lu R, Pan H, Shively JE -
Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1.
Cancer research 2012 Lu R, Kujawski M, Pan H, Shively JE -
Interaction of actin with carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) receptor in liposomes is Ca2+- and phospholipid-dependent.
The Journal of biological chemistry 2011 Lu R, Niesen MJ, Hu W, Vaidehi N, Shively JE